Arboretum Ventures

Type

Venture Capital

Status

Active

Location

Ann Arbor, United States

Total investments

102

Average round size

25M

Portfolio companies

60

Rounds per year

4.64

Lead investments

15

Follow on index

0.41

Exits

21

Stages of investment
Private EquityEarly Stage VentureLate Stage Venture
Areas of investment
BiotechnologySoftwareHealth CareHealth DiagnosticsHospitalManufacturingMedical DeviceMedicalPharmaceuticalTherapeutics

Summary

Arboretum Ventures is the famous VC, which was founded in 2002. The venture was found in North America in United States. The main office of represented VC is situated in the Ann Arbor.

The current fund was established by Jan Garfinkle, Tim Petersen. We also calculated 4 valuable employees in our database.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Arboretum Ventures, startups are often financed by Chrysalis Ventures, Lumira Ventures, ONSET Ventures. The meaningful sponsors for the fund in investment in the same round are Chrysalis Ventures, Baird Capital, ONSET Ventures. In the next rounds fund is usually obtained by Lumira Ventures, ONSET Ventures, Flagship Pioneering.

The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in 2-6 deals every year. The increased amount of exits for fund were in 2018. Considering the real fund results, this VC is 15 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Arboretum Ventures performs on 9 percentage points less the average number of lead investments. The important activity for fund was in 2013. Despite it in 2019 the fund had an activity.

Among the most successful fund investment fields, there are Medical, Hospital. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has specific favorite in a number of founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. Among the most popular portfolio startups of the fund, we may highlight Cardiac Dimensions, NeuMoDx Molecular, Delphinus Medical Technologies.

Show more

Investor highlights

Industry focus
Biotech/Life SciencesMedtechHealthcare
Stage focus
Series ASeries B
Geo focus
United States

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Last fund

Fund size
USD 268000000
Fund raised date
2023-07-10

Analytics

Total investments
102
Lead investments
15
Exits
21
Rounds per year
4.64
Follow on index
0.41
Investments by industry
  • Health Care (82)
  • Biotechnology (56)
  • Medical Device (44)
  • Medical (41)
  • Pharmaceutical (16)
  • Show 34 more
Investments by region
  • United States (100)
  • Canada (2)
Peak activity year
2021
Number of Minotaurs
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
13
Avg. valuation at time of investment
36M
Group Appearance index
0.96
Avg. company exit year
10
Avg. multiplicator
1.28
Strategy success index
0.40

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
AtaCor Medical 24 Apr 2024 Health Care, Medical Device Late Stage Venture 28M United States, California, San Clemente
Enumera Molecular 05 May 2022 Biotechnology, Life Science Early Stage Venture 12M United States, Ann Arbor, Michigan

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.